Table of Contents
Managing patients on direct oral anticoagulants (DOACs) who are undergoing surgical procedures requires careful planning and coordination. Proper management minimizes bleeding risks while preventing thromboembolic events. Healthcare providers should follow evidence-based protocols tailored to individual patient needs.
Preoperative Assessment
Before surgery, evaluate the patient’s medical history, type of surgery, and bleeding risk. Determine the specific DOAC used, dosage, and timing of the last dose. Assess renal and hepatic function, as these influence DOAC clearance and bleeding risk.
Risk Stratification
- Low bleeding risk procedures (e.g., dental, minor dermatologic surgeries)
- High bleeding risk procedures (e.g., major abdominal, orthopedic, neurosurgery)
Risk stratification guides management strategies, including whether to continue, modify, or temporarily discontinue DOAC therapy.
Perioperative Management Strategies
Continuation of DOACs
For low bleeding risk procedures, continuing DOACs may be appropriate. Ensure the last dose is taken within 24 hours before surgery, considering renal function.
Temporary Discontinuation
For high bleeding risk procedures, discontinue DOACs 48 hours prior, or 24 hours in patients with normal renal function. Restart postoperatively once hemostasis is secured.
Bridging Therapy
Bridging with heparin or low molecular weight heparin is generally not recommended for DOAC patients due to rapid onset and offset of action. Consider only in exceptional cases.
Intraoperative and Postoperative Care
Minimize intraoperative bleeding by employing meticulous surgical techniques. Maintain adequate hemostasis and consider local measures such as topical agents or sutures.
Monitoring and Resumption
Monitor for bleeding complications postoperatively. Resume DOACs once bleeding risk is controlled, typically 24-48 hours after surgery, based on clinical judgment.
Special Considerations
Patients with impaired renal or hepatic function require individualized management plans. Emergency surgeries demand rapid assessment and potentially reversal agents if bleeding occurs.
Reversal Agents
Andexanet alfa and idarucizumab are available for specific DOACs. Use these agents in cases of severe bleeding or urgent surgery where bleeding risk is high.
Conclusion
Effective management of patients on DOACs undergoing surgery hinges on thorough assessment, risk stratification, and adherence to guidelines. Multidisciplinary collaboration ensures optimal outcomes and patient safety.